Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Preferred Dividend Payments (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Preferred Dividend Payments for 5 consecutive years, with $166133.0 as the latest value for Q4 2019.

  • On a quarterly basis, Preferred Dividend Payments rose 10.38% to $166133.0 in Q4 2019 year-over-year; TTM through Jun 2020 was $328214.0, a 47.63% decrease, with the full-year FY2020 number at $166133.0, down 73.42% from a year prior.
  • Preferred Dividend Payments was $166133.0 for Q4 2019 at Outlook Therapeutics, up from $162081.0 in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $1.0 million in Q1 2016 to a low of $150508.0 in Q4 2018.
  • A 5-year average of $429850.9 and a median of $308467.0 in 2017 define the central range for Preferred Dividend Payments.
  • Biggest YoY gain for Preferred Dividend Payments was 10.38% in 2019; the steepest drop was 75.77% in 2019.
  • Outlook Therapeutics' Preferred Dividend Payments stood at $939539.0 in 2015, then crashed by 47.51% to $493207.0 in 2016, then dropped by 8.6% to $450801.0 in 2017, then crashed by 66.61% to $150508.0 in 2018, then grew by 10.38% to $166133.0 in 2019.
  • Per Business Quant, the three most recent readings for OTLK's Preferred Dividend Payments are $166133.0 (Q4 2019), $162081.0 (Q3 2019), and $158128.0 (Q2 2019).